SKIN-CAD – Biocom Systems, Inc.

Biocom Systems is a developer of SKIN-CAD, the only simulation software for transdermal and topical drug delivery.

SKIN-CAD Users and Publications

SKIN-CAD Users and Publications

[SKIN-CAD total users]

  • Kyushu Institute of Technology and National Cancer Center (limited term user)
  • 13 Japanese companies including Hisamitsu Pharmaceuticals Co., Inc. and Taisho Pharmaceuticals Co., Ltd.
  • Loughborough University (UK) and Oxford University (UK)
  • 2 European pharmaceutical companies and 1 US pharmaceutical company

[SKIN-CAD publications]

  1. Iwao, Y.1; Matsuoka, K.1; Okada, K.1; Minami, K.2; Yuasa, S.2 (1 Nitto Denko Corporation, 2 Toa Eiyo Ltd.) Percutaneous administration device of bisoprolol, US 8703178 B2, 2014.
  2. Hikima, T.1; Komatsu, M.1; Mori, D.2; Tojo, K.1 (1 Kyushu Institute of Technology, 2 Biocom Systems, Inc.) Prediction of Percutaneous Absorption in Human of Nicotine from Marketed TTS using Three-dimensional Human Cultured Epidermis, 40th Annual Meeting & Exposition of the Controlled Release Society, Honolulu, Hawaii, July 21-24, 2013.
  3. Saeki, Y.; Nishimura, M.; Matsuoka, K.; Muraoka, T.; Hosaka, Y.; Hori, M.; Ninomiya, K.; Akemi, H.; Kuroda, H. (Nitto Denko Corporation) Adhesive preparation containing fentanyl, US 8591939 B2, 2013.
  4. Hikima, T.; Kaneda, N.; Matsuo, K.; Tojo, K. (Kyushu Institute of Technology) Prediction of percutaneous absorption in human using three-dimensional human cultured epidermis LabCyte EPI-MODEL, Biol. Pharm. Bull. 2012, 35(3), 362-368.
  5. Nakamura, A.1,2; Mori, D.3; Tojo, K.1 (1 Kyushu Institute of Technology, 2 Yutoku Pharmaceutical Industries Co., Ltd., 3 Biocom Systems, Inc.) Evaluation of the predicted time-concentration profile of serum tulobuterol in human after transdermal application, Chem. Pharm. Bull. 2012, 60(3), 300-305.
  6. Olatunji, O.; Das, D.B.; Nassehi, V. (Loughborough University) Modelling transdermal drug delivery using microneedles: Effect of geometry on drug transport behaviour, J. Pharm. Sci. 2012, 101(1), 164-175.
  7. Tominaga, K.1,2; Tojo, K.1 (1 Kyushu Institute of Technology, 2 Kyoritsu Pharmaceutical Industries Co., Ltd.) Effect of environmental temperature on transdermal drug penetration, Biol. Pharm. Bull. 2010, 33(12), 1983-1987.
  8. Amano, S.; Honma, S.; Tateishi, T. (Hisamitsu Pharmaceutical Co., Inc.) Patch, US20100227932 A1, 2010.
  9. Yoshitake, M.; Ga, K. (Yutoku Pharmaceutical Industries Co., Ltd.) Riluzole-containing transdermal patch, WO2010113225 A1, 2010.
  10. Tojo, K.; Kimura, C. (Kyushu Institute of Technology) Solid Ophthalmic Drug for External Use, US 20100160293 A1, 2010.
  11. Al-Qallaf, B.1; Mori, D.3; Olatunji, L.2; Das, D.B.2; Cui, Z.1 (1 Oxford University, 2 Loughborough University, 3 Biocom Systems, Inc.) Transdermal drug delivery by microneedles: Does skin metabolism matter? Int. J. Chem. React. Eng. 2009, 7, A69 (pp.1-23).
  12. Olatunji, O.1; Das, D.B.1; Al-Qallaf, B.2 (1 Loughborough University, 2 Oxford University) Simulation based optimization of microneedle geometry to improve drug permeability in skin, 7th Annual Industrial Simulation Conference (ISC’2009), Loughborough, UK, June 1-3, 2009.
  13. Al-Qallaf, B.1; Das, D.B.2; Davidson, A.1 (1 Oxford University, 2 Loghborough University) Transdermal drug delivery by coated microneedles: geometry effects on drug concentration in blood, Asia-Pacific J. Chem. Eng. 2009, 4(6), 845-857.
  14. Al-Qallaf, B.1; Das, D.B.2 (1 Oxford University, 2 Loughborough University) Optimization of square microneedle arrays for increasing drug permeability in skin, Chem. Eng. Sci. 2008, 63, 2523-2535.
  15. Kimura, C.; Tojo, K. (Kyushu Institute of Technology) Stick-type transdermal delivery system for ocular diseases, 2007 AAPS Annual Meeting and Exposition, San Diego, CA, November 10-15, 2007.
  16. Tojo, K.; Hikima, T. (Kyushu Institute of Technology) Bioequivalence of marketed transdermal delivery systems for tulobuterol, Biol. Pharm. Bull. 2007, 30(8), 1576-1579.
  17. Al-Qallaf, B.1; Das, D.B.1; Mori, D.2; Cui, Z.1 (1 Oxford University, 2 Biocom Systems, Inc.) Modelling transdermal delivery of high molecular weight drugs from microneedle systems, Phil. Trans. R. Soc. A 2007, 365(1861), 2951–2967.
  18. Kimura, C.; Tojo, K. (Kyushu Institute of Technology) Development of a stick-type transdermal eyelid delivery system of ketotifen fumarate for ophthalmic diseases, Chem. Pharm. Bull. 2007, 55(7), 1002-1005.
  19. Mori, D.1; Tojo, K.2 (1 Biocom Systems, Inc., 2 Kyushu Institute of Technology) SKIN-CAD®: Pharmacokinetic model for transdermal drug delivery, 2006 AIChE Annual Meeting, San Francisco, CA, November 12-17, 2006.
  20. Terahara, T.; Toshimitsu, A.; Uemura, K.; Higo, N.; Goto, T.; Sato, S. (Hisamitsu Pharmaceutical Co., Inc.) Percutaneous absorption preparations, US 20040258741 A1, 2004.
  21. Isowaki, A.1; Ohtori, A.1; Matsuo, Y.2; Tojo, K.2 (1 Senju Pharmaceutical Co., Ltd., 2 Kyushu Institute of Technology) Drug delivery to the eye with a transdermal therapeutic system, Biol. Pharm. Bull. 2003, 26(1), 69-72.
  22. Mori, D.1; Kawamata, H.1,2; Tojo, K.1 (1 Kyushu Institute of Technology, 2 Taiho Pharmaceutical Co., Ltd.) Drug concentration – time profile in the plasma following the dissolution-type transdermal delivery, J. Chem. Eng. Japan 2003, 36(1), 45-48.
  23. Mori, D.; Tojo, K. (Kyushu Institute of Technology) In silico evaluation for skin pharmacokinetics, 29th Annual Meeting & Exposition of the Controlled Release Society, Seoul, Korea, July 20-25, 2002.
  24. Kawamata, H.1,2; Tojo, K.1 (1 Kyushu Institute of Technology, 2 Taiho Pharmaceutical Co., Ltd.) Prediction of plasma concentration of GTS-21 in hairless rats following monolithic transdermal delivery, Biol. Pharm. Bull. 2002, 25(3), 342-345.



« »